A recent article in the McGill Reporter reports on a new clinical trial at The Neuro (Montreal Neurological Hospital Institute) exploring the efficacy of an approved treatment to block the hyperactive cells responsible for the disconnection between nerves and muscles in ALS.

Dr. Richard Robitaille, mentioned in the article, explains how he and his team are approaching this specific feature of ALS in a distinct way.

The promising results of the pre-clinical tests hold out great hope for the success of future clinical trials in humans.

For more details on this research, please read the full article.

© McGill Reporter

Share this article.